Q3 Earnings Estimate for FBIO Issued By HC Wainwright

Key Points

• HC Wainwright forecasts that Fortress Biotech will report a Q3 2025 earnings per share of ($0.43), with a "Buy" rating and a price target of $17.00.
• In its latest earnings release, Fortress Biotech missed consensus estimates, reporting ($0.46) EPS, compared to the expected ($0.31).
• Institutional investors hold 96.51% of Fortress Biotech's stock, with notable increases in positions from various hedge funds recently.

Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) - Equities researchers at HC Wainwright issued their Q3 2025 earnings estimates for Fortress Biotech in a note issued to investors on Thursday, August 21st. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings of ($0.43) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $17.00 target price on the stock. The consensus estimate for Fortress Biotech's current full-year earnings is ($3.28) per share. HC Wainwright also issued estimates for Fortress Biotech's Q4 2025 earnings at $0.49 EPS, FY2025 earnings at ($1.18) EPS, FY2026 earnings at ($2.54) EPS and FY2027 earnings at ($1.97) EPS.

Fortress Biotech Stock Performance

Shares of NASDAQ FBIO traded up $0.06 during midday trading on Monday, hitting $2.35. The company's stock had a trading volume of 889,377 shares, compared to its average volume of 297,595. The stock has a fifty day moving average price of $1.94 and a 200 day moving average price of $1.78. Fortress Biotech has a one year low of $1.33 and a one year high of $2.49. The company has a current ratio of 1.92, a quick ratio of 1.70 and a debt-to-equity ratio of 1.34. The firm has a market capitalization of $69.91 million, a price-to-earnings ratio of -2.24 and a beta of 1.76.

Fortress Biotech (NASDAQ:FBIO - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.15). Fortress Biotech had a negative net margin of 24.84% and a negative return on equity of 301.81%. The business had revenue of $16.41 million during the quarter, compared to the consensus estimate of $14.53 million.

Institutional Trading of Fortress Biotech

Several hedge funds and other institutional investors have recently modified their holdings of the business. Panagora Asset Management Inc. bought a new stake in shares of Fortress Biotech in the second quarter valued at approximately $93,000. XTX Topco Ltd bought a new stake in Fortress Biotech during the 2nd quarter worth approximately $42,000. 180 Wealth Advisors LLC increased its holdings in Fortress Biotech by 6.4% during the 2nd quarter. 180 Wealth Advisors LLC now owns 93,050 shares of the biopharmaceutical company's stock worth $173,000 after acquiring an additional 5,600 shares during the period. Shikiar Asset Management Inc. increased its holdings in Fortress Biotech by 18.0% during the 2nd quarter. Shikiar Asset Management Inc. now owns 278,469 shares of the biopharmaceutical company's stock worth $518,000 after acquiring an additional 42,500 shares during the period. Finally, PFG Investments LLC increased its holdings in Fortress Biotech by 22.4% during the 2nd quarter. PFG Investments LLC now owns 55,419 shares of the biopharmaceutical company's stock worth $103,000 after acquiring an additional 10,160 shares during the period. Institutional investors own 96.51% of the company's stock.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.